FrancophonIA/ELRC3.0 huggingface dataset:
English: Very common ≥1/10 Common ≥1/100 to <1/10 Uncommon ≥1/1,000 to <1/100 Rare
Slovenian: (≥ 1/1 000 do < 1/100)
English: Feeling hot Fatigue Asthenia Chills Local swelling Non-cardiac chest pain Chest discomfort
Slovenian: Lokalne otekline Nekardialna bolečina v prsnem košu Neprijeten občutek v prsnem košu
English: low blood volume or low blood pressure; - Have moderate to severe liver problems or severe kidney problems, as these organs have an effect on the way in which your body breaks down and eliminates the medicine; have abnormally slow bowel movements; - Have a disease of the gall bladder or pancreas; - Have a history of medicine or alcohol abuse;
Slovenian: kako vaše telo razgrajuje in izloča to zdravilo; imate nenormalno počasno črevesno gibanje; - imate bolezen žolčnika ali trebušne slinavke;
English: Respiratory Depression
Slovenian: Depresija dihanja
English: Contents of the pack and other information What Dzuveo contains - The active substance is sufentanil.
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Dzuveo
English: - Muscle twitching and spasms.
Slovenian: - Trzanje mišic in krči.
English: The duration of activity may be prolonged in patients with severe hepatic and renal impairment.
Slovenian: Pri bolnikih s hudo jetrno in ledvično okvaro je lahko njegovo delovanje podaljšano.
English: Thrombocytopenia
Slovenian: Anemija Levkocitoza
English: Interaction with cytochrome P450-3A4 enzyme
Slovenian: 4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Interakcija z encimom citokrom P450-3A4
English: - Diarrhoea, burping or belching, inflammation of stomach lining or gastritis, bloating, acid reflux,
Slovenian: Driska, bruhanje ali spahovanje, vnetje želodčne sluznice ali gastritis, napenjanje, kislinski refluks, vzdigovanje, bolečina v želodcu ali neprijeten občutek v želodcu.
English: Annex IV Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
Slovenian: ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO
English: Urinary retention Urinary hesitation Oliguria
Slovenian: Zastajanje urina Težave z začetkom mokrenja Oligurija Odpoved ledvic
English: You should not drive or operate machinery if you experience any of these symptoms whilst or after being treated with sufentanil.
Slovenian: Če se pri vas med zdravljenjem s sufentanilom ali po njem pojavi kateri koli od teh simptomov, ne smete voziti ali upravljati strojev.
English: Talk to your doctor or nurse before using Dzuveo.
Slovenian: Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Dzuveo se posvetujte z zdravnikom ali medicinsko sestro.
English: Sufentanil as a μ-opioid receptor agonist may slow the gastrointestinal motility.
Slovenian: Učinki na prebavila Sufentanil kot μ-opioidni agonist lahko upočasni gastrointestinalno motiliteto, zato ga je treba pri bolnikih, pri katerih obstaja tveganje za ileus, zelo previdno.
English: In a study of a sufentanil 15 microgram sublingual tablet (with the same formulation as the 30 microgram tablet), a substantially lower bioavailability of 9% after oral intake (swallowed) was observed.
Slovenian: mikrogramski tableti) je bila po peroralnem vnosu (če se pogoltne) opažena bistveno nižja, 9
English: Hypoaesthesia oral
Slovenian: Ortostatska hipertenzija
English: Patient weight and age are key covariates on clearance.
Slovenian: Ključni sočasni spremenljivki očistka sta telesna masa in starost bolnika.
English: Miosis
Slovenian: Mioza
English: Tremor Ataxia Dystonia Hyperreflexia Tremor Burning sensation Presyncope Paraesthesia Hypoaesthesia Lethargy Memory impairment Migraine
Slovenian: Presinkopa Parestezije Hipestezija Letargija Motnje spomina Migrena
English: Keep this medicine out of the sight and reach of children.
Slovenian: Zdravilo shranjujte nedosegljivo otrokom.
English: OTHER
Slovenian: Eritem
English: Therefore, sufentanil should be used with caution in patients with biliary tract disease, including acute pancreatitis.
Slovenian: Sufentanil kot μ-opioidni agonist lahko povzroči krč Oddijevega sfinktra, zato ga je treba pri bolnikih z boleznijo žolčnika in žolčevodov, vključno z akutnim pankreatitisom, uporabljati previdno.
English: Nervous system disorders
Slovenian: Konverzivna motnja Dezorientiranost
English: Hepatic impairment
Slovenian: Epigastrično nelagodje
English: Pusher
Slovenian: Potiskalo
English: Impaired hepatic or renal function
Slovenian: Okvarjeno delovanje jeter ali ledvic
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SINGLE-DOSE APPLICATOR
Slovenian: PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
English: What Dzuveo looks like and contents of the pack Dzuveo is a blue-coloured, flat-faced sublingual tablet with round edges.
Slovenian: Dzuveo je modro obarvana podjezična tableta z ravnima ploskvama in okroglimi robovi.
English: retching, stomach pain or an uncomfortable stomach.
Slovenian: Nelagoden občutek v trebuhu Napet trebuh
English: Paediatric population
Slovenian: Lokalna toleranca
English: Blood urea increased Electrocardiogram T wave abnormal
Slovenian: Zvišana raven aspartat aminotransferaze Zvišana sečnina v krvi Nenormalen val T na elektrokardiogramu Nenormalen elektrokardiogram Zvišani jetrni encimi Nenormalen izvid preiskav delovanja jeter
English: Tell your doctor or nurse before treatment if you: - Are suffering from any condition that affects your breathing (such as asthma, wheezing, or shortness of breath).
Slovenian: - imate katero koli bolezen, ki vpliva na vaše dihanje (npr. astmo, piskanje ali kratko sapo).
English: Others
Slovenian: SERIJ
English: (tingling, skin crawling), numbness in general, tiredness, forgetfulness, migraine, tension headaches.
Slovenian: Težave pri usklajevanju mišičnih gibov, mišični krči, tresavica ali pretirano tresenje, pretirani refleksni odzivi, pekočina, občutek omedlevice, nenormalen občutek na koži (ščemenje, mravljinčenje), omrtvičenost na splošno, utrujenost, pozabljivost, migrena, tenzijski glavobol.
English: Sufentanil may produce bradycardia.
Slovenian: - Učinkovina je sufentanil.
English: Anaemia Leukocytosis
Slovenian: Žilne bolezni
English: An opiate antagonist (e.g. naloxone) should be administered in the event of respiratory depression.
Slovenian: Če se pojavi depresija dihanja, je treba dati opiatni antagonist (npr. nalokson).
English: - Any medicines which might make you sleepy (have a sedative effect), such as sleeping pills, medicines to treat anxiety (e.g. benzodiazipines), tranquillisers or other opioid medicines, as they can increase the risk of severe breathing problems, coma and may be life-threatening.
Slovenian: - katero koli zdravilo, ki bi lahko povzročilo zaspanost (deluje sedativno), npr. uspavalne tablete,
English: Drug withdrawal syndrome
Slovenian: Odtegnitveni sindrom
English: Renal failure Urinary tract pain
Slovenian: Bradipneja Epistaksa Kolcanje Apneja
English: The European Commission granted a marketing authorisation valid throughout the European Union for Mirvaso on 21 February 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Mirvaso, veljavno po vsej Evropski uniji, odobrila dne 21. februarja 2014.
English: Mirvaso brimonidine
Slovenian: Mirvaso brimonidin
English: Mirvaso should not be used in children or adolescents aged from 2 to 18 years.
Slovenian: Zdravilo Mirvaso se ne sme uporabljati pri otrocih in mladostnikih, starih od 2 do 18 let.
English: What measures are being taken to ensure the safe and effective use of Mirvaso?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Mirvaso?
English: The full EPAR and risk management plan summary for Mirvaso can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Mirvaso sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Mirvaso.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Mirvaso.
English: Rosacea is a skin condition affecting mainly the face.
Slovenian: Rozacea je bolezen kože, ki v glavnem prizadene obraz.
English: Regarding safety, the CHMP acknowledged that the safety profile is acceptable since most of the adverse events reported occur locally (on the skin) and are similar to those commonly observed with other rosacea medicines applied to the skin.
Slovenian: Kar zadeva varnost, je odbor CHMP ugotovil, da je varnostni profil sprejemljiv, saj se neželeni dogodki, o katerih poročajo, večinoma pojavijo lokalno (na koži) in so podobni tistim, ki jih pogosto opažajo pri uporabi drugih zdravil za rozaceo, ki se nanašajo na kožo.
English: Mirvaso has been evaluated in two main studies involving a total of 553 patients with moderate or severe facial redness caused by rosacea.
Slovenian: Zdravilo Mirvaso so ovrednotili v dveh glavnih študijah, v katerih je sodelovalo skupno 553 bolnikov z zmerno ali hudo rdečino obraza zaradi rozacee.
English: It is not intended to provide practical advice on how to use Mirvaso.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Mirvaso is available as a gel (3 mg/g) and can only be obtained with a prescription.
Slovenian: Zdravilo Mirvaso je na voljo v obliki gela (3 mg/g) in se izdaja le na recept.
English: A risk management plan has been developed to ensure that Mirvaso is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Mirvaso je bil pripravljen načrt obvladovanja tveganj.
English: Mirvaso must not be used in children below 2 years of age or in patients receiving other medicines such as monoamine oxidase (MAO) inhibitors or certain antidepressants.
Slovenian: Zdravilo Mirvaso se ne sme uporabljati pri otrocih, mlajših od 2 let, in pri bolnikih, ki uporabljajo druga zdravila, kot so zaviralci monoamin-oksidaze (MAO) ali določeni antidepresivi.
English: What are the risks associated with Mirvaso?
Slovenian: Kakšna tveganja so povezana z zdravilom Mirvaso?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Mirvaso's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Mirvaso večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: Mirvaso should only be applied to the skin of the face.
Slovenian: Zdravilo Mirvaso je treba nanašati izključno na kožo na obrazu.
English: What benefits of Mirvaso have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Mirvaso izkazalo v študijah?
English: What is Mirvaso and what is it used for?
Slovenian: Kaj je zdravilo Mirvaso in za kaj se uporablja?
English: Both studies showed that Mirvaso applied once a day was more effective than placebo at reducing the facial redness in these patients.
Slovenian: Obe študiji sta pokazali, da je bilo zdravilo Mirvaso, ki so ga nanašali enkrat na dan, učinkovitejše od placeba pri zmanjšanju rdečine obraza pri teh bolnikih.
English: For more information about treatment with Mirvaso, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Mirvaso preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Mirvaso is a medicine that contains the active substance brimonidine tartrate.
Slovenian: Mirvaso je zdravilo, ki vsebuje zdravilno učinkovino brimonidinijev tartrat.
English: Why is Mirvaso approved?
Slovenian: Zakaj je bilo zdravilo Mirvaso odobreno?
English: The main measure of effectiveness was the percentage of patients who achieved a marked reduction of facial redness at different time points (3, 6, 9 and 12 hours) on days 1, 15 and 29 after the start of the treatment.
Slovenian: Glavno merilo učinkovitosti je bil odstotek bolnikov, pri katerih so zabeležili izrazito zmanjšanje rdečine obraza ob različnih časovnih točkah (3, 6, 9 in 12 ur) 1., 15. in 29. dan po začetku zdravljenja.
English: The most common side effects with Mirvaso (which may affect more than 1 in 100 people), which are usually mild to moderate in severity, are erythema (redness), pruritus (itching), flushing and a burning sensation of the skin.
Slovenian: Najpogostejši neželeni učinki zdravila Mirvaso (ki lahko prizadenejo več kot 1 osebo od 100), ki so običajno blagi do zmerni, so eritem (rdečina), pruritus (srbenje), vročinski vali in občutek skelenja na koži.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Mirvaso, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Mirvaso in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: Symptoms include episodes of redness that have been linked to the widening of small blood vessels in the skin of the face, which increases the blood flow to the area.
Slovenian: Simptomi vključujejo epizode rdečine, ki so povezane z razširitvijo majhnih krvnih žil v koži na obrazu, zaradi katere se poveča pretok krvi v ta predel.
English: The active substance in Mirvaso, brimonidine tartrate, works by attaching to receptors called alpha2adrenergic receptors on the cells of blood vessels of the skin and activating them.
Slovenian: Zdravilna učinkovina v zdravilu Mirvaso, brimonidinijev tartrat, deluje tako, da se veže na receptorje na celicah krvnih žil v koži, imenovane alfa2-adrenergični receptorji, in jih aktivira.
English: It is used to treat the facial erythema (redness of the skin of the face) in adults with rosacea, a long-term skin condition that often causes flushing and redness.
Slovenian: Uporablja se za zdravljenje obraznega eritema (pordelosti kože na obrazu) pri odraslih z rozaceo, tj. dolgotrajno boleznijo kože, ki pogosto povzroča zardevanje in rdečino.
English: Other information about Mirvaso
Slovenian: Druge informacije o zdravilu Mirvaso
English: For practical information about using Mirvaso, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Mirvaso naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: This causes these blood vessels to narrow, which reduces the blood flow to the face, thus decreasing the redness.
Slovenian: S tem povzroči, da se krvne žile zožijo, s čimer se zmanjša pretok krvi v obraz in posledično tudi rdečina.
English: Both studies compared Mirvaso with placebo (a dummy gel) over four weeks of treatment.
Slovenian: V obeh študijah so zdravilo Mirvaso primerjali s placebom (gelom brez zdravilne učinkovine) med štiritedenskim zdravljenjem.
English: Effects were also maintained for 12 hours after application and started to wear off after 6 hours.
Slovenian: Učinki so prav tako trajali še 12 ur po nanosu in so po 6 urah začeli popuščati.
English: For the full list of side effects reported with Mirvaso, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Mirvaso, glejte navodilo za uporabo.
English: The CHMP concluded that Mirvaso improves the facial redness in patients with rosacea.
Slovenian: Odbor CHMP je zaključil, da zdravilo Mirvaso zmanjša rdečino obraza pri bolnikih z rozaceo.
English: Small amounts of gel (about pea size) are applied to the skin of the forehead, chin, nose and cheeks once a day as a thin layer.
Slovenian: Majhne količine gela (približno v velikosti grahovega zrna) se enkrat na dan v tanki plasti nanesejo na kožo na čelu, bradi, nosu in licih.
English: Effects were maintained for 12 hours after application although the effects started to wear off after 6 hours.
Slovenian: Učinki so trajali še 12 ur po nanosu, vendar so po 6 urah začeli popuščati.
English: The areas should be left to dry out before applying other creams or cosmetics.
Slovenian: Pred nanosom drugih krem ali kozmetičnih izdelkov je treba počakati, da se ti predeli posušijo.
English: How is Mirvaso used?
Slovenian: Kako se zdravilo Mirvaso uporablja?
English: How does Mirvaso work?
Slovenian: Kako zdravilo Mirvaso deluje?
English: • In the first study, on day 1 the percentage or patients who had reduction of facial redness 3 hours after application was 16.3% (21 out of 129) for Mirvaso compared with 3.1% (4 out of 131) for placebo.
Slovenian: • V prvi študiji je na 1. dan odstotek bolnikov, pri katerih se je 3 ure po nanosu rdečina obraza zmanjšala, znašal 16,3 % (21 od 129) za zdravilo Mirvaso in 3,1 % (4 od 131) za placebo.
English: • In the second study, on day 1 the percentage or patients who had reduction of facial redness 3 hours after application was 19.6% (29 out of 148 patients) for Mirvaso compared with 0 % (none out of 145 patients) for placebo.
Slovenian: • V drugi študiji je na 1. dan odstotek bolnikov, pri katerih se je rdečina obraza zmanjšala 3 ure po nanosu, znašal 19,6 % (29 od 148 bolnikov) za zdravilo Mirvaso in 0 % (nobeden od 145 bolnikov) za placebo.
English: On day 29, 25.4% (36 out of 142) of patients had reduction of facial redness 3 hours after application with Mirvaso compared with a response of 9.2 % (13 out of 142) for placebo.
Slovenian: Na 29. dan se je 3 ure po nanosu rdečina obraza zmanjšala pri 25,4 % (36 od 142) bolnikov, ki so uporabljali zdravilo Mirvaso, v primerjavi z 9,2 % (13 od 142) bolnikov, ki so uporabljali placebo.
English: On day 29, 31.5% (40 out of 127) patients had reduction of facial redness 3 hours after application with Mirvaso compared with a response of 10.9% (14 out of 128) for placebo.
Slovenian: Na 29. dan se je 3 ure po nanosu rdečina obraza zmanjšala pri 31,5 % (40 od 127) bolnikov, ki so uporabljali zdravilo Mirvaso, v primerjavi z 10,9 % (14 od 128) bolnikov, ki so uporabljali placebo.
English: This overview was last updated in 08-2018.
Slovenian: Pregled je bil nazadnje posodobljen 08-2018.
English: Further information on Dexdor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Nadaljnje informacije o zdravilu Dexdor so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Dexdor?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Dexdor?
English: In some cases, the patient is also given a local anaesthetic, painkillers and other sedative medicines.
Slovenian: V nekaterih primerih bolnik prejme tudi lokalni anestetik, protibolečinska zdravila in druga sedativna zdravila.
English: The European Medicines Agency therefore decided that Dexdor's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Dexdor večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Dexdor received a marketing authorisation valid throughout the EU on 16 September 2011.
Slovenian: Za zdravilo Dexdor je bilo 16. septembra 2011 izdano dovoljenje za promet, veljavno po vsej EU.
English: Sedation in intensive care
Slovenian: Sedacija v intenzivni negi
English: • in hospital intensive care units to bring about a light level of sedation in which the patient can still respond to verbal stimulation (corresponding to a score of between 0 and -3 on the Richmond Agitation-Sedation Scale);
Slovenian: • na bolnišničnih oddelkih za intenzivno nego za doseganje sorazmerno blage stopnje sedacije, pri kateri se bolnik še vedno lahko odziva na verbalno stimulacijo (kar ustreza rezultatu med 0 in -3 po Richmondovi lestvici agitacije - sedacije);
English: Patients in the Dexdor group received either 0.5 or 1 microgram/kg bodyweight.
Slovenian: Bolniki v skupini, zdravljeni z zdravilom Dexdor, so prejemali 0,5 ali 1 mikrograma/kg telesne mase.
English: The main measures of effectiveness were how well the medicines maintained the required sedation level and the time patients needed to spend on a mechanical ventilator (a machine that ‘breathes' for the patient).
Slovenian: Glavni merili učinkovitosti sta bili, kako dobro je zdravilo vzdrževalo želeno stopnjo sedacije, in čas, ki ga je bolnik moral preživeti na mehanski ventilaciji (napravi, ki pomaga bolniku dihati).
English: The studies also showed that Dexdor reduced the duration of mechanical ventilation.
Slovenian: Študiji sta pokazali tudi, da zdravilo Dexdor skrajša trajanje mehanske ventilacije.
English: Dexdor (dexmedetomidine)
Slovenian: Dexdor (deksmedetomidin)
English: • before or during diagnostic or surgical procedures where the patient remains awake (awake sedation).
Slovenian: • pred ali med diagnostičnimi ali kirurškimi posegi, pri katerih bolnik ostane buden (sedacija v budnem stanju).
English: As dexmedetomidine has been in use in several countries as a sedative agent, its risks are well known and are considered to be manageable.
Slovenian: Ker se deksmedetomidin kot sedativ že uporablja v več državah, so njegova tveganja dobro znana in obvladljiva.
English: As for all medicines, data on the use of Dexdor is continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Dexdor stalno spremljajo.
English: Other information about Dexdor
Slovenian: Druge informacije o zdravilu Dexdor
English: Awake sedation during diagnostic or surgical procedures
Slovenian: Sedacija v budnem stanju med diagnostičnim ali kirurškim posegom
English: It works by blocking receptors in the brain called alpha-2 receptors and reduces the activity of the sympathetic nervous system which is involved in controlling anxiety, arousal and sleep as well as blood pressure and heart rate.
Slovenian: Deluje tako, da zavira receptorje v možganih, imenovane receptorji alfa-2, in zmanjša delovanje simpatičnega živčnega sistema, ki vpliva na nadzorovanje tesnobe, vznemirjenosti in spanja ter na krvni tlak in srčni utrip.
English: Why is Dexdor authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Dexdor odobreno v EU?
English: The active substance in Dexdor, dexmedetomidine, is a selective alpha-2 receptor agonist.
Slovenian: Učinkovina v zdravilu Dexdor, deksmedetomidin, je selektivni agonist receptorjev alfa-2.
English: What benefits of Dexdor have been shown in studies?
Slovenian: Kakšne koristi zdravila Dexdor so se pokazale v študijah?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dexdor have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Dexdor upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: If sedation with the maximum dose is not adequate, the patient can be switched to other medicines.
Slovenian: Če stopnja sedacije z največjim odmerkom ni zadostna, se lahko uporabijo druga zdravila.
English: An overview of Dexdor and why it is authorised in the EU
Slovenian: Pregled zdravila Dexdor in zakaj je odobreno v EU
English: The first study involved patients undergoing surgery or a procedure under an anaesthetic block (where sensation to a part of the body is blocked).
Slovenian: Prva študija je vključevala bolnike, pri katerih je bil opravljen kirurški poseg ali postopek pod anestetično blokado (pri kateri je zavrto zaznavanje v določenem delu telesa).